BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/6/2020 7:54:48 AM | Browse: 1196 | Download: 2441
 |
Received |
|
2019-12-17 14:55 |
|
Peer-Review Started |
|
2019-12-17 14:55 |
|
First Decision by Editorial Office Director |
|
2020-02-20 23:11 |
|
Return for Revision |
|
2020-02-20 23:11 |
|
Revised |
|
2020-03-05 08:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-03-09 15:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-03-09 17:43 |
|
Articles in Press |
|
2020-03-09 17:43 |
|
Edit the Manuscript by Language Editor |
|
2020-03-21 04:08 |
|
Typeset the Manuscript |
|
2020-04-03 11:58 |
|
Publish the Manuscript Online |
|
2020-04-06 07:54 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Hui Guo, Yuan-Yuan Wang, Jiang-Wei Zhang, Pei-Min Liu, Yan-Jun Hao and Hai-Rui Duan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81872032 |
|
| Corresponding Author |
Jun-Hui Guo, MAMS, MPhil, Chief Doctor, Department of Oncology, The Second Affiliated Hospital of Henan University of Chinese Medicine, Henan Province Hospital of TCM, No. 6 Dongfeng Road, Zhengzhou 450002, Henan Province, China. gjunhui2008@163.com |
| Key Words |
Esophageal squamous cell carcinoma; Cervical adenocarcinoma; Brain micrometastases; Apatinib; Tyrosine kinase inhibitor; Vascular endothelial growth factor |
| Core Tip |
Brain metastases are the most common intracranial tumor, the average survival time of patients after symptomatic treatment with chemotherapy, radiotherapy and hormonal drugs is less than 1 year. We report two patients with multiple micrometastases in the brain after failure of second-line treatment, and both had extracerebral metastases. By taking apatinib, the intracerebral lesions disappeared and the extracerebral lesions were partially alleviated. Both patients received progression-free survival for more than 12 mo and are still stable. Apatinib, a small-molecule oral inhibitor with anti-angiogenic function, may be an option for brain metastases. |
| Publish Date |
2020-04-06 07:54 |
| Citation |
Guo JH, Wang YY, Zhang JW, Liu PM, Hao YJ, Duan HR. Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. World J Clin Cases 2020; 8(7): 1326-1336
|
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i7/1326.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i7.1326 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
